Trial Profile
Safety and efficacy of low-dose Dasatinib (50 mg) in patients with newly-diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 Jun 2017
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 16 Jun 2017 New trial record
- 06 Jun 2017 Early results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology